FGL1 Protein Characterization for Cancer Detection

Part of the fibrinogen protein family, FGL1 is expressed at low levels in the liver under usual conditions. By contrast, this protein is highly expressed in various types of cancers such as melanoma and prostate cancer.

According to a recent study, FGL1 protein is a hot immune inhibitory ligand of LAG-3 products. Therefore, inhibiting the interaction between FGL1 and LAG-3 would not only improve the body’s immunity but would also slow down the growth of tumors.

ACROBiosystems has developed HEK293-expressed FGL1 protein with a wide range of tags (His, Fc) and species (Mouse, Human, Cyno). The company has also developed AviTagTM biotinylated FGL1 protein that can help in developing drugs. Moreover, ACROBiosystems has validated the activity and purity of FGL1 protein and also offers protocols.

Application

Product List

Molecule Cat. No. Host Product Description Product Status
FGL1
(HEK293 expressed)
FG1-H5253 Human Human FGL1 Protein, Fc Tag Launched
FG1-H82F3 Human Biotinylated Human FGL1 Protein, Fc Tag, Avi Tag (Avitag™)
FG1-M5255 Mouse Mouse FGL1 Protein, Fc Tag
FG1-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque FGL1 Protein, Fc Tag
FG1-H52H7 Human Human FGL1 Protein, His Tag Coming soon
FG1-H82E5 Human Biotinylated Human FGL1 Protein, His Tag, Avi Tag (Avitag™)
FG1-M5253 Mouse Mouse FGL1 Protein, Mouse IgG2a Fc Tag
FG1-C5256 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque FGL1 Protein, Mouse IgG2a Fc Tag

 

As cited above, FGL1 protein has been recognized as a hot immune inhibitory ligand of LAG-3 products.

Bioactivity

Bioactivity of FGL1 was Validated by ELISA

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 10 μg/mL (100 μL/well) can bind Biotinylated Human FGL1, Fc Tag, Avi Tag (Cat. No. FG1-H82F3) with a linear range of 0.156–1.25 μg/mL.

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 10 μg/mL (100 μL/well) can bind Biotinylated Human FGL1, Fc Tag, Avi Tag (Cat. No. FG1-H82F3) with a linear range of 0.156–1.25 μg/mL.

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 20 μg/mL (100 μL/well) can bind Human FGL1, Fc Tag (Cat. No. FG1-H5253) with a linear range of 5–78 ng/mL.

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 20 μg/mL (100 μL/well) can bind Human FGL1, Fc Tag (Cat. No. FG1-H5253) with a linear range of 5–78 ng/mL.

Immobilized Mouse LAG-3, His Tag (Cat. No. LA3-M52H5) at 20 μg/mL (100 μL/well) can bind Mouse FGL1, Fc Tag (Cat. No. FG1-M5255) with a linear range of 0.078–1.25 μg/mL.

Immobilized Mouse LAG-3, His Tag (Cat. No. LA3-M52H5) at 20 μg/mL (100 μL/well) can bind Mouse FGL1, Fc Tag (Cat. No. FG1-M5255) with a linear range of 0.078–1.25 μg/mL.

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 5 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque FGL1, Fc Tag (Cat. No. FG1-C5253) with a linear range of 8–125 ng/mL.

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 5 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque FGL1, Fc Tag (Cat. No. FG1-C5253) with a linear range of 8–125 ng/mL.

*Customers can contact ACROBiosystems if they wish to add further experimental design and application data of FGL1 protein. If they have any custom-made product or more suggestion for FGL1 protein, they can explore the development suggestion section.

About ACROBiosystems

ACROBiosystems is an internationally recognized manufacturer of recombinant proteins committed to supporting cancer immunotherapy. We specialize in mammalian cell-based recombinant protein production and process development.

Our goal is to support professionals from pharmaceutical companies, CROs and research institutes who are working on the cancer immunotherapy area by providing high-quality proteins, antibodies and assay kits.

We have multiple offices and branches in North America, Europe, and Asia, and we are proud of serving customers from over 50 countries.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Aug 14, 2019 at 4:01 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2019, August 14). FGL1 Protein Characterization for Cancer Detection. News-Medical. Retrieved on October 20, 2019 from https://www.news-medical.net/whitepaper/20190814/FGL1-Protein-Characterization-for-Cancer-Detection.aspx.

  • MLA

    ACROBiosystems. "FGL1 Protein Characterization for Cancer Detection". News-Medical. 20 October 2019. <https://www.news-medical.net/whitepaper/20190814/FGL1-Protein-Characterization-for-Cancer-Detection.aspx>.

  • Chicago

    ACROBiosystems. "FGL1 Protein Characterization for Cancer Detection". News-Medical. https://www.news-medical.net/whitepaper/20190814/FGL1-Protein-Characterization-for-Cancer-Detection.aspx. (accessed October 20, 2019).

  • Harvard

    ACROBiosystems. 2019. FGL1 Protein Characterization for Cancer Detection. News-Medical, viewed 20 October 2019, https://www.news-medical.net/whitepaper/20190814/FGL1-Protein-Characterization-for-Cancer-Detection.aspx.

Other White Papers by this Supplier